Stability and change in mother-child reminiscing following intervention: Pandemic and reminiscing and emotion training influences.

Dev PsycholJan 2, 2025 (epub)
Clinical ResearchPsychiatryPediatricsOpen access

Kristin Valentino, Katherine Edler, Karen P Jacques et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial followed mothers and children to examine whether Reminiscing and Emotion Training (RET), child maltreatment history, and the COVID-19 pandemic were associated with maternal elaboration and sensitive guidance during reminiscing. Five years after intervention, 166 families completed an assessment when children were aged 8–12 years. Piecewise growth models across five waves found that mothers assigned to RET remained higher in elaboration and sensitive guidance than mothers receiving case management, while the case-management group remained lower than the nonmaltreatment comparison group. Reminiscing trajectories were stable from T2 to T5, and pandemic onset had no significant effect.

Key findings

  • At five-year follow-up, RET mothers remained higher in elaboration and sensitive guidance than mothers in the case-management condition.
  • Mothers in the case-management group remained lower in elaboration and sensitive guidance than the nonmaltreatment comparison group.
  • All three groups showed stable reminiscing trajectories from T2 to T5 after intervention-related change between T1 and T2.
  • Pandemic onset did not significantly affect maternal reminiscing at T5 or its change from T2 to T5.

Why it matters

The findings suggest that improvements in how mothers discuss past events with children can persist across developmental periods after an intervention. Such conversations involve both elaboration and emotionally sensitive guidance, making their sustained change relevant to understanding parent-child interaction over time. The absence of a detected pandemic effect also provides context for interpreting the follow-up results collected across the pandemic’s onset.

What to keep in mind

The follow-up included 166 of the original 248 families, so results reflect a subset of the initial trial participants.

Source

Published in Dev Psychol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.